Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials - PubMed
Few prodromal Alzheimer's disease (AD) trial papers discuss biomarker disclosure. Disclosure has implications for participants, family members, and trial success. Disclosure must be consistently...
pubmed.ncbi.nlm.nih.gov